Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Interest Expenses (2016 - 2026)

Ocular Therapeutix has reported Interest Expenses over the past 14 years, most recently at $2.8 million for Q1 2026.

  • For Q1 2026, Interest Expenses fell 6.94% year-over-year to $2.8 million; the TTM value through Mar 2026 reached $11.6 million, down 7.06%, while the annual FY2025 figure was $11.8 million, 12.83% down from the prior year.
  • Interest Expenses for Q1 2026 was $2.8 million at Ocular Therapeutix, down from $2.8 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $4.2 million in Q4 2023 and troughed at $1.7 million in Q1 2022.
  • A 5-year average of $2.7 million and a median of $3.0 million in 2025 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: soared 129.13% in 2024 and later fell 26.34% in 2025.
  • Year by year, Interest Expenses stood at $1.8 million in 2022, then surged by 124.74% to $4.2 million in 2023, then fell by 25.17% to $3.1 million in 2024, then fell by 8.82% to $2.8 million in 2025, then fell by 1.94% to $2.8 million in 2026.
  • Business Quant data shows Interest Expenses for OCUL at $2.8 million in Q1 2026, $2.8 million in Q4 2025, and $3.0 million in Q3 2025.